Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

The Phase II VENTURE-Oral Dosing study of VK2735 met primary and secondary endpoints, with once-daily treatment leading to progressive weight reductions, high responder rates, and encouraging safety ...

GLP-1 receptor agonists like semaglutide and the dual GIP/GLP-1 agonist tirzepatide mimic naturally occurring hormones that ...

Serena Williams recently shared that she started taking the GLP-1 drug Zepbound after having her two children. The tennis ...

In summary, decreased levels of circulating GLP-1 and GIP appear to be primarily responsible for the impaired ability of the type 2 diabetes patient to mount an effective postprandial insulin ...

The incretin therapies, which start with GLP-1, and now I'll look at GLP-1 and GIP, for me foundationally changed our treatment of diabetes because they have the benefit of being potent agents ...

Adults with type 2 diabetes assigned a novel dual GIP/GLP-1 receptor agonist for 40 weeks experienced significant reductions in HbA1c and body weight compared with those assigned placebo ...

Serena Williams says she has lost weight using GLP-1 medication. The drugs help manage blood sugar and promote weight loss, ...

The increasing amount of patients with obesity and type 2 diabetes benefit greatly from the recently developed GIPR:GLP-1R co-agonists. These novel compounds lead to substantial weight loss ...

Both GLP-1 and GIP are rapidly cleaved by dipeptidyl peptidase-4 (DPP-4). GLP-1 is a product of a precursor molecule called pre-proglucagon, a polypeptide which is split to produce many hormones ...

With an average HbA1c reduction of up to 2.4% and weight loss of up to 11.3 kg with the highest dose, the investigational GIP/GLP-1 dual agonist LY3298176 impresses in patients with type 2 diabetes.